Level of Attrition from Antiretroviral Therapy Among Human Immune Deficiency Virus-Infected Children: The Cases of Sidama Zone, Southern Ethiopia

被引:1
|
作者
Sifr, Zemenu [1 ]
Ando, Telto [1 ]
Semeon, Wosenyeleh [1 ]
Rike, Muse [1 ]
Ashami, Kidist [2 ]
机构
[1] Hawassa Coll Hlth Sci, Dept Hlth Informat Technol, POB 84, Hawassa, Ethiopia
[2] Harvard Grad Sch Arts & Sci, Boston, MA 02138 USA
来源
关键词
lost to follow-up; attrition; HIV-infected children; ART; Sidama zone; FOLLOW-UP; HIV; OUTCOMES; LOST; PREDICTORS; CENTERS; AFRICA; CARE;
D O I
10.2147/HIV.S317117
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Human immune deficiency virus (HIV) remains one of the leading causes of infectious disease mortality and morbidity in Sub-Saharan Africa. Although remarkable progress has been made in prevention and treatment of HIV, there is a higher rate of loss to follow-up in HIV-infected children than in adults, once they enter care. Objective: To determine the incidence and identify predictors of loss to follow-up among HIV-infected children on anti-retroviral treatment in Sidama Zone, Ethiopia. Methods: A retrospective cohort study was done among children that were enrolled in ART care in Sidama Zone from September 2014 to August 2018. A total of 143 eligible children were included in this study. A structured checklist was used to extract data from patients' medical records such as patient intake forms, electronic database, and registers. Data were entered, cleaned, coded, and analyzed by STATA version 12. Cox proportional hazards models were fitted to investigate predictors of loss to follow-up. Results: Of the 143 participants, 76 (53.15%) were female children with a median age of 7 years and interquartile range of 4-9. The incidence rate was 5 per 100 person-years and the cumulative incidence 12.59%. The median follow-up time was 2.46 years and the total time at risk was 356.06 person-years. Furthermore, 55.56% and 72.22% of those lost to follow-up were within the first and the second years of follow-up, respectively. In multivariable Cox proportional model, only the TB status of the children was significantly associated with loss to follow-up with hazard ratio 3.348 [1.174831, 9.543494] and p-value of 0.024. Conclusion: In this study, TB status of children was the significant determinant of loss to follow-up. However, the overall retention was 87.4% and a substantially higher proportion of loss was observed within the first and second years of follow-up.
引用
收藏
页码:813 / 822
页数:10
相关论文
共 50 条
  • [21] Effect of Intercurrent Infections and Vaccinations on Immune and Inflammatory Biomarkers Among Human Immunodeficiency Virus-Infected Adults on Suppressive Antiretroviral Therapy
    Tan, Darrell H. S.
    Szadkowski, Leah
    Raboud, Janet
    Yi, Tae Joon
    Shannon, Brett
    Kaul, Rupert
    Liles, W. Conrad
    Walmsley, Sharon
    OPEN FORUM INFECTIOUS DISEASES, 2015, 2 (02):
  • [22] Effect of potent antiretroviral therapy on immune responses to Mycobacterium avium in human immunodeficiency virus-infected subjects
    Havlir, DV
    Schrier, RD
    Torriani, FJ
    Chervenak, K
    Hwang, JY
    Boom, WH
    JOURNAL OF INFECTIOUS DISEASES, 2000, 182 (06): : 1658 - 1663
  • [23] Short course directly observed therapy to monitor compliance with antiretroviral, therapy in human immunodeficiency virus-infected children
    Gigliotti, F
    Murante, BL
    Weinberg, GA
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2001, 20 (07) : 716 - 718
  • [24] The association between caregiver knowledge of antiretroviral therapy regimens and disease parameters among perinatally human immunodeficiency virus-infected children
    Nicholson, Ouzama
    Mellins, Claude
    Dolezal, Curtis
    Santamaria, E. Karina
    Brackis-Cott, Elizabeth
    Abrams, Elaine J.
    ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE, 2006, 160 (12): : 1307 - 1308
  • [25] Effects of the change from stavudine to tenofovir in human immunodeficiency virus-infected children treated with highly active antiretroviral therapy
    Rosso, Raffaella
    Nasi, Milena
    Di Biagio, Antonio
    Repetto, Ernestina
    Dentone, Chiara
    Pinti, Marcello
    Nemes, Elisa
    Ferraresi, Roberta
    Mussini, Cristina
    Esposito, Roberto
    Viscoli, Claudio
    Cossarizza, Andrea
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2008, 27 (01) : 17 - 21
  • [26] Impact of Antiretroviral Therapy on the Risk of Herpes Zoster among Human Immunodeficiency Virus-Infected Individuals in Tanzania
    Kawai, Kosuke
    Hawkins, Claudia A.
    Hertzmark, Ellen
    Francis, Joel M.
    Sando, David
    Muya, Aisa N.
    Ulenga, Nzovu
    Fawzi, Wafaie W.
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2018, 98 (02): : 396 - 401
  • [27] Incidence of Tuberculosis and Associated Mortality in a Cohort of Human Immunodeficiency Virus-Infected Children Initiating Antiretroviral Therapy
    Salvadori, Nicolas
    Ngo-Giang-Huong, Nicole
    Duclercq, Chloe
    Kanjanavanit, Suparat
    Ngampiyaskul, Chaiwat
    Techakunakorn, Pornchai
    Puangsombat, Achara
    Figoni, Julie
    Mary, Jean-Yves
    Collins, Intira J.
    Cressey, Tim R.
    Le Coeur, Sophie
    Sirirungsi, Wasna
    Lallemant, Marc
    McIntosh, Kenneth
    Jourdain, Gonzague
    JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY, 2017, 6 (02) : 161 - 167
  • [28] Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected children
    Granados, JMS
    Amador, JTR
    De Miguel, SF
    Tomé, MIG
    Conejo, PR
    Vivas, PF
    Pollán, JC
    Contreras, JR
    Espert, AN
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2003, 22 (10) : 863 - 867
  • [29] Marked dyslipidemia in human immunodeficiency virus-infected children on protease inhibitor-containing antiretroviral therapy
    Lainka, E
    Oezbek, S
    Falck, M
    Ndagijimana, J
    Niehues, T
    PEDIATRICS, 2002, 110 (05) : e56
  • [30] Mortality and its predictors among human immunodeficiency virus-infected children younger than 15 years receiving antiretroviral therapy in Ethiopia: a systematic review and meta-analysis
    Woldegeorgis, Beshada Zerfu
    Asgedom, Yordanos sisay
    Gebrekidan, Amanuel Yosef
    Kassie, Gizachew Ambaw
    Borko, Ushula Deboch
    Obsa, Mohammed Suleiman
    BMC INFECTIOUS DISEASES, 2024, 24 (01)